• Result of the votes at Theradiag’s Annual and Extraordinary General Meeting
  • Change in the composition of the Board of Directors chaired by Gérard Tobelem 
  • The Board of Directors reaffirms its confidence in the CEO
  • Update regarding the HOB Biotech situation

Croissy-Beaubourg, June 5, 2018, 8am CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, today announces the results of the voting at its Ordinary Annual and Extraordinary General Meeting.

Results of the voting at the Ordinary Annual and Extraordinary General Meeting

The Company’ Ordinary Annual and Extraordinary General Meeting was held on May 29, 2018 in the offices of the Fieldfisher law firm, 48 rue Cambon, 75001 Paris, France. The number of shares held by shareholders present or represented at the Meeting was 2,536,253, giving a quorum of 29.27%.

The results of the votes of Theradiag’s shareholders at this Meeting were as follows:

Change in the composition of the Board of Directors

Following this AGM, Theradiag’s Board of Directors still comprises seven members and has just one new member, Sylvie Bratel, who has declared herself to be an independent director. The composition of the Board of Directors is thus now as follows:

  • Gérard Tobelem, Chairman of the Board
  • Sylvie Bratel, Independent Director
  • Dominique Costantini, Independent Director
  • Vincent Fert, Independent Director
  • John Li, Director
  • Pierre Morgon, Independent Director
  • Dominique Takizawa, Independent Director

After completing engineering degrees in France and the United States, in 1982 Sylvie Bratel joined Banque Nationale de Paris to work on technological innovation projects. She continued her career with the General Inspectorate and the Balance Sheet Management department before joining the Caisse des Dépôts et Consignation group in 1995, where she worked in the Competitive Banking Activities and Strategy departments. She participated in the creation of CDC-Markets before steering merger operations with Groupe Caisse d’Epargne and Groupe des Banques Populaires with the creation of Natixis. From 2009 to 2014, Sylvie Bratel was Head of Strategy for British insurance company Aviva’s French subsidiary and then VP of its life insurance subsidiary Aviva Vie. Since 2014, Sylvie Bratel, independent director, has been IFA and EcoDa certified.

The Board of Directors reaffirms its confidence in the CEO

At its meeting of June 4, 2018, the Board of Directors confirmed Michel Finance’s mandate as CEO and reaffirmed its full and complete confidence in him.

Update regarding the HOB Biotech situation

HOB Biotech’s failure to comply with the terms of the 2015 contractual agreements signed by both companies has led to Theradiag being unable to distribute the agreed products in Europe or to market its reagents in China. Because of the loss suffered by Theradiag, legal proceedings have been initiated against HOB Biotech in order to obtain compensation.

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases and cancer. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. The Company is based in Marne-la-Vallée, near Paris, and has over 65 employees.

For more information about Theradiag, please visit our website: www.theradiag.com


Investor Relations

Fabienne François


Tel.: +33 (0)1 64 62 10 12



Financial Communications

& Investor Relations

Valentine Brouchot

Tel.: +33 (0)1 44 71 94 94


Alize RP

Press Relations

Caroline Carmagnol

Tel.: +33 (0)1 44 54 36 64